Blue Cross NC Immunoglobulin Medical Policy Update
Effective October 1, 2022, the Immunoglobulin Medical Policy (PDF) will be updated to include preferred products in both the subcutaneous (SC) and intravenous (IV) immune globulin products. Providers must try preferred SC products and IV products before utilizing non-preferred products. This change will only impact patients who are new to therapy. Patients currently in therapy will not be impacted.
This change applies to all commercial, Administrative Services Only (ASO) and State Health Plan members. This policy does not apply to FEP (Federal Employee Program) or Medicare members.
- Preferred IV products: Octagam, Gamunex-C, Gammaked, Gammagard Liquid, Privigen
- Preferred SC products: Hizentra, Xembify
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.